1 November 2022 06:37 p.m. All figures in US dollars. bluebird bio Inc is expected to show an increase in its third quarter earnings to $-1.12 per share according to the mean Refinitiv estimate from ten analysts. Wall Street expects results to range from a loss of $-1.30 to a loss of -88 cents per share. RECOMMENDATIONS * The consensus recommendation for the company is "Hold". This includes one "Buy", eight "Hold", * The average consensus recommendation for the biotechnology & medical research peer group is also "Hold". FORECAST CHANGES * Eleven analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There were no changes to the number of estimates. * In the last four weeks the earnings per share estimate has risen by 0.18 percent from $-1.11. Estimates ranged from a high of -88 cents to a low of $-1.28. There has been no changes to the number of estimates. * The StarMine predicted earnings surprise is too low to be considered statistically significant. Predicted revenue surprise is too low to be significant. * The average price target from the eleven analysts providing estimates is $7.56. YEAR OVER YEAR * The company is expected to report a fall in revenue to $1 million from $22.68 million in the same quarter last year. * The current quarter consensus estimate of $-1.12 per share implies a gain of 64.65 percent from the same quarter last year when the company reported $-3.16 per share. * Previous quarterly performance (using preferred earnings measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Jun. 30 2022 -1.24 -1.27 Missed Mar. 31 2022 -1.39 -1.66 Missed Dec. 31 2021 -1.88 -2.14 Missed Sep. 30 2021 -2.59 -3.16 Missed This summary was machine generated from Refinitiv data November 1 at 06:37 p.m..